Alternative Data for Stoke Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,010 | Sign up | Sign up | Sign up |
| X Followers | 1,562 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 87 | Sign up | Sign up | Sign up |
| Linkedin Employees | 192 | Sign up | Sign up | Sign up |
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.
| Price | $36.48 |
| Target Price | Sign up |
| Volume | 750,326 |
| Market Cap | $2.19B |
| Year Range | $11.48 - $38.35 |
| Dividend Yield | 0% |
| PE Ratio | 56.4 |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
Forecasting The Future: 5 Analyst Projections For Stoke TherapeuticsFebruary 23 - Benzinga |
Wolfe Research Initiates Coverage On Stoke Therapeutics with Outperform Rating, Announces Price Target of $40February 23 - Benzinga |
|
Stoke Therapeutics Doses The First Patient In Phase 1 OSPREY Study Of STK-002 For Autosomal Dominant Optic AtrophyFebruary 10 - Benzinga |
|
 |
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's OpportunityJanuary 14 - SeekingAlpha |
 |
Stoke Therapeutics, Inc. (STOK) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 13 - SeekingAlpha |
 |
Stoke Therapeutics price target raised by $4 at Wedbush, here's whyJanuary 12 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 11M | 0 | 0 | -38M | -39M | -0.650 |
| Q2 '25 | 14M | 1.1M | 14M | -23M | -27M | -0.400 |
| Q1 '25 | 159M | 1.1M | 159M | 113M | 112M | 1.900 |
| Q4 '24 | 23M | 1.1M | 23M | -10M | -13M | -0.180 |
| Q3 '24 | 4.9M | 1.1M | 4.9M | -26M | -29M | -0.469 |
Insider Transactions View All
| Krainer Adrian R. filed to sell 316,545 shares at $39.7. March 4 '26 |
| Kaye Edward M. MD filed to sell 49,124 shares at $33.1. December 10 '25 |
| Kaye Edward M. MD filed to sell 58,729 shares at $31.4. December 10 '25 |
| Kaye Edward M. MD filed to sell 50,455 shares at $32.5. December 10 '25 |
| Allan Jonathan filed to sell 14,509 shares at $31.6. December 10 '25 |
Similar companies
Read more about Stoke Therapeutics (STOK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Stoke Therapeutics
The Market Cap of Stoke Therapeutics is $2.19B.
As of today, Stoke Therapeutics' PE (Price to Earnings) ratio is 56.4.
Currently, the price of one share of Stoke Therapeutics stock is $36.48.
The STOK stock price chart above provides a comprehensive visual representation of Stoke Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Stoke Therapeutics shares. Our platform offers an up-to-date STOK stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Stoke Therapeutics (STOK) does not offer dividends to its shareholders. Investors interested in Stoke Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Stoke Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
